MXenes are synthesized from ‘MAX’ phases by the selective etching of ‘A’ layers. The MAX phases are conductive 2D layers of transition metal carbides/nitrides interconnected by the ‘A’ element with strong ionic, metallic, and covalent bonds.
Figure 1. (A) The periodic table highlighting the ‘M’, ‘A’, and ‘X’ elements of known MAX phases. (B) Schematic illustration of the synthesis of MXenes from MAX phases. Reprinted with permission from Ref. [46]. Copyright © 2022 Wiley.
Scheme 1. Biomedical applications of MXenes.| MXene-Based Drug Carrier | Stimuli for Drug Release | Drug | Advantages | Ref. |
|---|---|---|---|---|
| Ti3C2Tx-SP | pH, NIR | Doxorubicin | High drug-loading capability of 211.8%. | [47] |
| Ti3C2Tx-CoNWs | pH, NIR | Doxorubicin | High drug-loading capacity of 225.05%. | [49] |
| Ti3C2Tx@GNRs/PDA/Ti3C2Tx | NIR | Doxorubicin | 95.88% drug-loading ability. | [50] |
| Ti3C2Tx/Polyacrylamide | pH | Chloramphenicol | Ti3C2Tx/Polyacrylamide hydrogels exhibited a high drug-loading of 97.5–127.7 mg/g and drug release percentages of 62.1–81.4%. | [53] |
| HAP/CS/HA/MXene/AuNRs | pH, NIR | Doxorubicin | Drug encapsulation efficiency of 83.9% | [54] |
| Polymer-coated MXene nanobelt fibers | NIR | Vitamin E | NIR-induced relaxation of the interface by the polymeric coating layer to dissolve and release Vitamin E. | [55] |
| Ti3C2Tx@Agarose hydrogel | NIR | Doxorubicin | The DOX-loaded MXene-hydrogel exhibited rapid DOX release under NIR the irradiation, while almost no DOX release when NIR was turned off, proving an NIR switch for controlled drug release. | [56] |
| MXene@Agarose | NIR | HGF | Flexible and controllable release of the protein drugs with high precision. | [57] |
| MXenes-FA-SP | pH | Doxorubicin | Drug-loading capacity of 69.9% and 48 h long drug release time. | [58] |
| Ti3C2Tx@Met@CP | pH, NIR | Metformin | The functionalized Ti3C2Tx nanosheets in the composite exhibited effective singlet oxygen generation, strong NIR absorption, and high photothermal conversion efficiency of ~59.6%. | [59] |
| Ti2N@oSi | NIR | Doxorubicin | Ultrahigh drug-loading capacity of 796.3%. | [60] |
| MXene@MOF-5@DOX | pH | Doxorubicin/pCRISPR | Achieved a drug payload of 35.7%. | [61] |
| MXene/Composite | Antimicrobial Applications | Ref. |
|---|---|---|
| Ti3C2Tx | Antibacterial activity against E. coli and B. subtilis with 98% viability loss within 4 h. | [62] |
| Colloidal Ti3C2Tx | Antibacterial activity against B. subtilis and E. coli. | [63] |
| Ti3C2Tx | Antibacterial activity against E. coli. | [65] |
| Ti3C2Tx | Photocatalytic inactivation of airborne E. coli. | [69] |
| Bi2S3/Ti3C2Tx | Photoexcited antimicrobial effects on S. aureus and E. coli. | [70] |
| Ti3C2Tz/Chitosan | Antibacterial activity against E. coli and S. aureus. | [71] |
| Nb2CTx and Nb4C3Tx | Bactericidal property against E. coli and S. aureus. | [72] |
| Cu2O/Ti3C2Tx | Antibacterial activity against S. aureus and Pseudomonas aeruginosa. | [73] |
| Ti3C2Tx-AuNCs | Antibacterial performance on S. aureus and E. coli. | [74] |
| MoS2/Ti3C2Tx | Antibacterial activity against E. coli and B. subtilis. | [75] |
| Ti3C2Tx-Laden bacteriophage | Antibacterial activity against Shigella. | [76] |
| Ag/Ti3C2Tx | Inhibitory activity against E. coli and S. aureus. | [77] |
| TiVCTX | Antibacterial activities against E. coli, photothermal sterilization effect on E. coli and B. subtilis. | [78] |
| CuP-sTi3C2Tx | Antibacterial activity against E. coli and S. aureus. | [79] |
| Ti3C2Tx | Size-dependent photothermal antibacterial activity against S. aureus. | [80] |
| Ti3C2Tx/PVA hydrogel | Antibacterial activity against E. coli and S. aureus. | [81] |
| V2C NSs | Antibacterial activity against E. coli, and B. subtilis. | [82] |
| BC/Chi/Ti3C2Tx/AgNWs aerogel | Antibacterial activity against E. coli and S. aureus. | [83] |
This entry is adapted from the peer-reviewed paper 10.3390/bios12070454